Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Established in 1960, CHA Health Systems (CHS) opened its first women’s medical center in Seoul, South Korea. CHS has received worldwide recognition and accolades for its excellence in clinical research and accomplishments in the fields of obstetrics and gynecology. It owns and operates, among others: Hollywood Presbyterian Medical Center, one of the largest privately-owned hospital in Los Angeles and 8 general acute-care hospital facilities throughout Korea. CHS continued its international expansion and formed CHAUM, a premier anti-aging center and 5 fertility treatment and research centers in the U.S. and Korea. The Company’s activities also include various medical and biotech ventures, including a healthcare investment firm, CHA Bio & Diostech, one of the largest biotechs listed in KOSDAQ.
CHS also introduces a premier anti-aging center, CHAUM, offering various treatments including western medicine, alternative medicine, stem-cell therapies, exercise prescription, and food therapies, targeting issues related to optimum health and wellness. It also operates a global CHAUM clinical trial center, the world’s only one-stop clinical trial center for regenerative medicine. In this center, GMP facility, surgery room, recovery room, treatment room, and in-hospitalization facility are centrally located for convenience and quality care. Its customized clinical trial services and state-of-the art facilities for the development of regenerative medicine are a major supplier to many biotech companies worldwide, which offers opportunities for small and large companies to carry out proof of concept studies and early phase clinical trials at substantial savings in time and money.
With the ultimate vision of becoming a global leader in the next generation of healthcare services, CHS continues to stay at the forefront of medical services by building its global network of hospitals/clinics and research institutes for the advancement of bio-medicine and bio-ventures.
Contact Details
Dong-kun Lee, Corporate Planning
335 Pangyo-Ro, Bundang-Gu, Seongnam City, Kyunggi-Do, Republic of Korea
Tel. (+82)31-881-7370 Cell (+82)10-9261-6160 Fax. (+82)31-881-7379
E-mail. ddkk.lee@chamc.co.kr
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
See our Cookie Privacy Policy Here
